Business Context and Reporting Period
Company: Exelixis, Inc. (EXEL)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal Year 2025 (52 weeks ended January 2, 2026)
Business Overview: Exelixis is an oncology company focused on the discovery, development, and commercialization of medicines for difficult-to-treat cancers. Its revenue is primarily driven by the cabozantinib franchise (CABOMETYX and COMETRIQ). The company is advancing a pipeline of small molecules and biotherapeutics, with zanzalintinib as its lead clinical asset.
Key Financial Metrics
| Metric | Fiscal 2025 | Fiscal 2024 | Change |
|---|---|---|---|
| Total Revenues | $2,320.1 million | $2,168.7 million | +7% |
| Net Product Revenues | $2,122.8 million | $1,809.4 million | +17% |
| Collaboration Revenues | $197.3 million | $359.3 million | -45% |
| Net Income | $782.6 million | $521.3 million | +50% |
| Diluted EPS | $2.78 | $1.76 | +58% |
| Operating Cash Flow | $884.3 million | $700.0 million | +26% |
| Cash & Marketable Securities | $1.66 billion | $1.75 billion | -5% |
| Effective Tax Rate | 16.9% | 23.5% | -6.6 pts |
Debt & Liquidity: The company reported no long-term debt in the provided text. Liquidity is supported by $1.66 billion in cash, cash equivalents, and marketable securities. The company has authorized stock repurchase programs totaling $1.75 billion, with $590.2 million remaining available as of December 31, 2025.
Material Changes vs. Prior Period
- Revenue Growth: Net product revenues increased 17% year-over-year, driven by a 16% increase in CABOMETYX units sold (due to demand for RCC and new NET indications) and a 1% increase in average net selling price.
- Collaboration Revenue Decline: Collaboration revenues dropped 45% to $197.3 million. This was primarily due to a significant decrease in milestone revenues ($14.3 million in 2025 vs. $169.3 million in 2024), as 2024 included a $150 million commercial milestone from Ipsen.
- Expense Management: Research and Development (R&D) expenses decreased 9% to $825.0 million, driven by lower clinical trial costs for cabozantinib and reduced license/collaboration costs. Selling, General, and Administrative (SG&A) expenses increased 5% to $518.7 million due to marketing for new indications and higher stock-based compensation.
- Profitability: Net income increased significantly to $782.6 million, aided by higher revenues, lower R&D spend, and a reduced effective tax rate (16.9% vs. 23.5%) due to the Foreign-Derived Intangible Income (FDII) deduction and tax credits.
Guidance, Outlook, and Risks
Outlook and Management Commentary
- Zanzalintinib: In December 2025, Exelixis submitted a New Drug Application (NDA) to the FDA for zanzalintinib in combination with atezolizumab for metastatic colorectal cancer (CRC). The FDA accepted the NDA in January 2026 with a PDUFA target action date of December 3, 2026.
- CABOMETYX Expansion: The company continues to commercialize CABOMETYX for newly approved indications, including pancreatic and extra-pancreatic neuroendocrine tumors (pNET/epNET), approved in March 2025.
- Financial Projection: Management projects net product revenues may increase in fiscal 2026. R&D expenses are expected to increase due to clinical trials for zanzalintinib and biotherapeutics. SG&A is expected to rise due to salesforce expansion and marketing for zanzalintinib.
Risks and Contingencies
- Generic Competition: The company faces ongoing patent litigation regarding generic versions of CABOMETYX. While recent court rulings have delayed generic entry (e.g., MSN litigation), the risk of generic competition remains a material threat to future revenues.
- Regulatory & Pricing: The Inflation Reduction Act (IRA) introduces drug price negotiation and inflation rebates. Exelixis currently qualifies for the "small biotech exception" through 2027, but future pricing pressures are a key risk.
- Clinical Development: Success depends on the clinical performance of zanzalintinib and other pipeline assets. The company recently discontinued the XL495 program and the STELLAR-305 trial for head and neck cancer based on emerging data and competitive landscape assessments.
Key Facts for Investor Verification
- NDA Status: Verify the FDA review timeline and potential approval date for zanzalintinib in CRC (PDUFA date: Dec 3, 2026).
- Patent Litigation: Monitor the status of consolidated litigation against MSN, Sun, and Azurity regarding CABOMETYX patents, specifically the appeal of the MSN II ruling and the outcome of the Sun settlement.
- IRA Impact: Confirm the company's continued qualification for the "small biotech exception" under the IRA for the 2028 Initial Price Applicability Year (IPAY) and beyond.
- Stock Repurchases: Track the utilization of the remaining $590.2 million authorized under the October 2025 stock repurchase program.
- Collaboration Milestones: Assess the probability of future milestone payments from Ipsen and Takeda, which are highly variable and impacted by sales thresholds and regulatory approvals.